Pavlovsky S, Fernández I, Palau V, Santarelli M T, De Bellis R, Ruiz-Argüelles G, Brandalise S, Jiménez-Fonseca E
Instituto de Investigaciones Hematológicas Mariono R. Castex, Buenos Aires, Argentina.
Ann Oncol. 1991 Jun;2(6):441-2. doi: 10.1093/oxfordjournals.annonc.a057982.
This study tested the efficacy of rubidazone and cytosine arabinoside in 35 patients (13 children and 22 adults) with acute myelocytic leukemia in first relapse. Induction consisted of 1-2 courses of rubidazone 200 mg/m2 days x 4 days plus cytosine arabinoside 100 mg/m2 x 7 days in CI followed by 2 consolidation courses of 3 days and 5 days. Nineteen patients (54%) achieved complete remission, 8 failed to respond, and 8 died. Twelve patients relapsed after 1 to 9 months, at a median of 4 months, 1 patient died of cardiac failure and 1 remains in complete remission at 12 months. Five patients underwent bone marrow transplantation, 3 of them autologous, 1 was still in complete remission at 29 months, 1 relapsed, and 1 died of sepsis. Two received allogeneic marrow transplants and died at 3 and 4 months afterwards of VOD and graft failure. The main toxicity was severe and prolonged myelosuppression.
本研究对35例首次复发的急性髓细胞白血病患者（13例儿童和22例成人）进行了柔红霉素苯腙和阿糖胞苷疗效的测试。诱导治疗包括1 - 2个疗程，柔红霉素苯腙200mg/m² ，连用4天，加阿糖胞苷100mg/m² ，连用7天，持续静脉输注，随后进行2个巩固疗程，分别为3天和5天。19例患者（54%）达到完全缓解，8例无反应，8例死亡。12例患者在1至9个月后复发，中位复发时间为4个月，1例死于心力衰竭，1例在12个月时仍处于完全缓解状态。5例患者接受了骨髓移植，其中3例为自体移植，1例在29个月时仍处于完全缓解状态，1例复发，1例死于败血症。2例接受了异基因骨髓移植，分别在3个月和4个月后死于肝静脉闭塞病和移植失败。主要毒性为严重且持续时间长的骨髓抑制。
